Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1068-1074

  Overman, M J ^a   Morris, V ^a   Kee, B ^a   Fogelman, D ^a   Xiao, L ^a   Eng, C ^a   Dasari, A ^a   Shroff, R ^a   Mazard, T ^a   Shaw, K ^a   Vilar, E ^a   Raghav, K ^a   Shureiqi, I ^a   Liang, L ^a   Mills, G B ^a   Wolff, R A ^a   Hamilton, S ^a   Meric Bernstam, F ^a   Abbruzzese, J ^b   Morris, J ^a   Maru, D ^a   Kopetz, S ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Molecular; Prescreening; Screening; Targeted

Indexed keywords

FLUOROURACIL; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER GENETICS; CANCER SCREENING; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DISEASE MARKER; DNA METHYLATION; FEMALE; GENE SEQUENCE; GENETIC SCREENING; HEALTH PROGRAM; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; PATIENT CARE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESEARCH SUBJECT; STANDARD; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; ELIGIBILITY DETERMINATION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PATIENT SELECTION;

EID: 84974806547     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw073     Document Type: Article

References (11)

1. Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 2011; 29: 1236-1238.
2. Rodon J, Saura C, Dienstmann R et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 2012; 9: 359-366.
3. Meric-Bernstam F, Brusco L, Shaw K et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 2015; 33: 2753-2762.
4. Andre F, Bachelot T, Commo F et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014; 15: 267-274.
5. Kris MG, Johnson BE, Berry LD et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311: 1998-2006.
6. Chantrill LA, Nagrial AM, Watson C et al. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clin Cancer Res 2015; 21: 2029-2037.
7. Le Tourneau C, Delord JP, Goncalves A et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16: 1324-1334.
8. Lopez-Chavez A, Thomas A, Rajan A et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 2015; 33: 1000-1007.
9. Lara PN, Jr, Higdon R, Lim N et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001; 19: 1728-1733.
10. Go RS, Frisby KA, Lee JA et al. Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 2006; 106: 426-433.
11. Kaplan CP, Napoles AM, Dohan D et al. Clinical trial discussion, referral, and recruitment: physician, patient, and system factors. Cancer Causes Control 2013; 24: 979-988.